Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 7.94
CYNO's Cash to Debt is ranked higher than
71% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 4.48 vs. CYNO: 7.94 )
CYNO' s 10-Year Cash to Debt Range
Min: 2.24   Max: No Debt
Current: 7.94

Equity to Asset 0.80
CYNO's Equity to Asset is ranked higher than
84% of the 367 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. CYNO: 0.80 )
CYNO' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.87
Current: 0.8

0.48
0.87
F-Score: 3
Z-Score: 4.57
M-Score: -1.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -2.58
CYNO's Operating margin (%) is ranked higher than
59% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. CYNO: -2.58 )
CYNO' s 10-Year Operating margin (%) Range
Min: -27.9   Max: 15.75
Current: -2.58

-27.9
15.75
Net-margin (%) -0.73
CYNO's Net-margin (%) is ranked higher than
62% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 4.71 vs. CYNO: -0.73 )
CYNO' s 10-Year Net-margin (%) Range
Min: -31.25   Max: 12.72
Current: -0.73

-31.25
12.72
ROE (%) -0.50
CYNO's ROE (%) is ranked higher than
63% of the 368 Companies
in the Global Medical Devices industry.

( Industry Median: 5.93 vs. CYNO: -0.50 )
CYNO' s 10-Year ROE (%) Range
Min: -78.33   Max: 36.17
Current: -0.5

-78.33
36.17
ROA (%) -0.40
CYNO's ROA (%) is ranked higher than
63% of the 382 Companies
in the Global Medical Devices industry.

( Industry Median: 3.43 vs. CYNO: -0.40 )
CYNO' s 10-Year ROA (%) Range
Min: -41.35   Max: 18.91
Current: -0.4

-41.35
18.91
ROC (Joel Greenblatt) (%) -8.09
CYNO's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 381 Companies
in the Global Medical Devices industry.

( Industry Median: 13.35 vs. CYNO: -8.09 )
CYNO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -66   Max: 55.51
Current: -8.09

-66
55.51
Revenue Growth (%) 21.90
CYNO's Revenue Growth (%) is ranked higher than
95% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. CYNO: 21.90 )
CYNO' s 10-Year Revenue Growth (%) Range
Min: -13   Max: 24.8
Current: 21.9

-13
24.8
EBITDA Growth (%) 78.30
CYNO's EBITDA Growth (%) is ranked higher than
98% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. CYNO: 78.30 )
CYNO' s 10-Year EBITDA Growth (%) Range
Min: -74.3   Max: 86.6
Current: 78.3

-74.3
86.6
EPS Growth (%) -41.10
CYNO's EPS Growth (%) is ranked higher than
51% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: -1.70 vs. CYNO: -41.10 )
CYNO' s 10-Year EPS Growth (%) Range
Min: -41.1   Max: 210.1
Current: -41.1

-41.1
210.1
» CYNO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CYNO Guru Trades in Q2 2013

Steven Cohen 479,000 sh (+5064.42%)
Paul Tudor Jones 229,600 sh (+1168.51%)
Mario Gabelli 81,753 sh (+308.77%)
Jim Simons 157,622 sh (+31.11%)
» More
Q3 2013

CYNO Guru Trades in Q3 2013

Chuck Royce 3,600 sh (New)
Paul Tudor Jones 357,000 sh (+55.49%)
Jim Simons Sold Out
Steven Cohen 466,424 sh (-2.63%)
Mario Gabelli 23,686 sh (-71.03%)
» More
Q4 2013

CYNO Guru Trades in Q4 2013

Chuck Royce 255,600 sh (+7000%)
Mario Gabelli 23,686 sh (unchged)
Paul Tudor Jones 239,100 sh (-33.03%)
Steven Cohen 252,100 sh (-45.95%)
» More
Q1 2014

CYNO Guru Trades in Q1 2014

Paul Tudor Jones 259,322 sh (+8.46%)
Steven Cohen Sold Out
Chuck Royce 253,500 sh (-0.82%)
Mario Gabelli 20,250 sh (-14.51%)
» More
» Details

Insider Trades

Latest Guru Trades with CYNO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2013-09-30 Reduce -71.03%0.01%$21.65 - $28.48 $ 22.74-9%23686
Mario Gabelli 2013-06-30 Add 308.77%0.01%$23.12 - $27.37 $ 22.74-9%81753
Joel Greenblatt 2013-03-31 Sold Out 0.03%$24.11 - $29.85 $ 22.74-16%0
Joel Greenblatt 2012-12-31 New Buy0.03%$21.2 - $27.48 $ 22.74-7%18472
Charles Brandes 2012-03-31 Sold Out 0.01%$12 - $19.28 $ 22.7458%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.50
CYNO's P/B is ranked higher than
90% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.46 vs. CYNO: 1.50 )
CYNO' s 10-Year P/B Range
Min: 0.46   Max: 4.96
Current: 1.5

0.46
4.96
P/S 1.91
CYNO's P/S is ranked higher than
80% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 3.30 vs. CYNO: 1.91 )
CYNO' s 10-Year P/S Range
Min: 0.5   Max: 5.83
Current: 1.91

0.5
5.83
EV-to-EBIT -62.43
CYNO's EV-to-EBIT is ranked higher than
54% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 44.56 vs. CYNO: -62.43 )
CYNO' s 10-Year EV-to-EBIT Range
Min: 1.1   Max: 311.7
Current: -62.43

1.1
311.7
Current Ratio 3.96
CYNO's Current Ratio is ranked higher than
79% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. CYNO: 3.96 )
CYNO' s 10-Year Current Ratio Range
Min: 1.67   Max: 7.09
Current: 3.96

1.67
7.09
Quick Ratio 3.02
CYNO's Quick Ratio is ranked higher than
79% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 2.16 vs. CYNO: 3.02 )
CYNO' s 10-Year Quick Ratio Range
Min: 0.87   Max: 5.83
Current: 3.02

0.87
5.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.90
CYNO's Price/Net Cash is ranked higher than
89% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 14.90 )
CYNO' s 10-Year Price/Net Cash Range
Min: 1.5   Max: 22.4
Current: 14.9

1.5
22.4
Price/Net Current Asset Value 5.50
CYNO's Price/Net Current Asset Value is ranked higher than
94% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 5.50 )
CYNO' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 7.06
Current: 5.5

1.06
7.06
Price/Tangible Book 2.70
CYNO's Price/Tangible Book is ranked higher than
85% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 5.99 vs. CYNO: 2.70 )
CYNO' s 10-Year Price/Tangible Book Range
Min: 0.56   Max: 4.58
Current: 2.7

0.56
4.58
Price/DCF (Projected) 1.60
CYNO's Price/DCF (Projected) is ranked higher than
94% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. CYNO: 1.60 )
CYNO' s 10-Year Price/DCF (Projected) Range
Min: 1.05   Max: 2.09
Current: 1.6

1.05
2.09
Price/Median PS Value 0.90
CYNO's Price/Median PS Value is ranked higher than
88% of the 413 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. CYNO: 0.90 )
CYNO' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 2.67
Current: 0.9

0.32
2.67
Earnings Yield (Greenblatt) 5.20
CYNO's Earnings Yield (Greenblatt) is ranked higher than
81% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. CYNO: 5.20 )
CYNO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 94.8
Current: 5.2

0.3
94.8
Forward Rate of Return (Yacktman) 0.78
CYNO's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.97 vs. CYNO: 0.78 )
CYNO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.4   Max: 2.5
Current: 0.78

1.4
2.5

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:C9S.Germany
Cynosure, Inc., was incorporated under the laws of the State of Delaware in July 1991. The Company develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair rejuvenate the skin through the treatment of vascular and pigmented lesions, remove multi-colored tattoos, liquefy and remove unwanted fat through laser lypolysis, reduce cellulite and treat onychomycosis. It is also developing in conjunction with its development agreement with Unilever Ltd., (Unilever) a laser treatment system for the home use market. Its systems incorporate a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag and diode lasers, as well as intense pulsed light. It offers single energy source systems as well as workstations that incorporate two or more different types of lasers or pulsed light technologies. It offers multiple technologies and system alternatives at a variety of price points depending mainly on the number and type of energy sources included in the system. Its newer products are designed to be easily upgradeable to add additional energy sources and handpieces, which provide its customers with technological flexibility as they expand their practices. It sell its products through a direct sales force in North America, France, Spain, the United Kingdom, Germany, Korea, China, Japan and Mexico and through international distributors in 97 other countries. Its products competes against laser and other light-based products offered by public companies, such as Syneron Medical Ltd., Cutera, Inc., Palomar Medical Technologies, Inc. and Solta Medical, Inc. The Company's products are medical devices subject to extensive and rigorous regulation by the U.S. Food and Drug Administration, or FDA, as well as other regulatory bodies.
» More Articles for CYNO

Headlines

Articles On GuruFocus.com
old newsletter Apr 10 2012 
Cynosure Reports Second Quarter 2009 Financial Results Jul 28 2009 
Cynosure Inc. (CYNO) CFO Timothy W Baker buys 2,500 Shares Feb 27 2009 
Cynosure Inc. (CYNO) CEO Michael R Davin buys 2,500 Shares Feb 27 2009 
Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 Feb 10 2009 
Cynosure: A Value Play on Vanity Jan 18 2009 


More From Other Websites
Nasdaq stocks posting largest percentage increases Jul 31 2014
CYNOSURE INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 30 2014
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President Jul 30 2014
8:33 am Cynosure appoints COO/CFO Timothy Baker as President effective August 1, 2014 Jul 30 2014
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President Jul 30 2014
Cynosure (CYNO) in Focus: Stock Adds 17% in Session Jul 30 2014
Cynosure Inc Earnings Call scheduled for 9:00 am ET today Jul 29 2014
Cynosure Reports Second-Quarter 2014 Financial Results Jul 29 2014
CYNOSURE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2014
Cynosure Reports Second-Quarter 2014 Financial Results Jul 29 2014
Q2 2014 Cynosure Inc. Earnings Release - Before Market Open Jul 29 2014
Cynosure Receives Expanded FDA Clearance to Market PicoSure™ for Treatment of Acne Scars Jul 24 2014
Cynosure receives expanded FDA clearance to market Picosure Jul 24 2014
Cynosure Receives Expanded FDA Clearance to Market PicoSure™ for Treatment of Acne Scars Jul 24 2014
Cynosure To Host Second-Quarter 2014 Financial Results Conference Call On July 29 Jul 16 2014
Cynosure To Host Second-Quarter 2014 Financial Results Conference Call On July 29 Jul 16 2014
CYNOSURE INC Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's Employee Benefit... Jun 20 2014
Moving Average Crossover Alert: Cynosure (CYNO) May 30 2014
CYNOSURE INC Financials May 20 2014
What Falling Estimates & Price Mean for Cynosure (CYNO) May 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide